This study evaluated the effectiveness of sulindac, a nonsteroidal anti-inflammatory drug (NSAID), in reducing the number and size of colorectal adenomas in patients with familial adenomatous polyposis (FAP). The study was a randomized, double-blind, placebo-controlled trial involving 22 patients with FAP, including 18 who had not undergone colectomy. Patients received either sulindac (150 mg twice daily) or a placebo for nine months. The number and size of polyps were assessed every three months for one year. Results showed a statistically significant decrease in the mean number and diameter of polyps in the sulindac group compared to the placebo group. However, the effects were not complete, and the number and size of polyps increased after nine months of discontinuing sulindac. No adverse side effects were observed. The study concluded that while sulindac can reduce the number and size of polyps in FAP patients, it is unlikely to replace colectomy as the primary therapy.This study evaluated the effectiveness of sulindac, a nonsteroidal anti-inflammatory drug (NSAID), in reducing the number and size of colorectal adenomas in patients with familial adenomatous polyposis (FAP). The study was a randomized, double-blind, placebo-controlled trial involving 22 patients with FAP, including 18 who had not undergone colectomy. Patients received either sulindac (150 mg twice daily) or a placebo for nine months. The number and size of polyps were assessed every three months for one year. Results showed a statistically significant decrease in the mean number and diameter of polyps in the sulindac group compared to the placebo group. However, the effects were not complete, and the number and size of polyps increased after nine months of discontinuing sulindac. No adverse side effects were observed. The study concluded that while sulindac can reduce the number and size of polyps in FAP patients, it is unlikely to replace colectomy as the primary therapy.